Metabolism Disorder TRIZ Cases

CD63 biomarker assays improve lysosomal storage disease diagnosis and monitoring, including CNS involvement and therapy adjustment.

An oral GLP-1 formulation uses oils, bile salts, and sodium bicarbonate to avoid injection side effects while lowering glucose and body weight.

Meal-timed ROSE-010 dosing suppresses appetite and supports weight control while reducing nausea and vomiting from longer-acting GLP-1 agonists.

A 2-pyridone THRβ agonist uses a stable crystal form to improve receptor selectivity, reduce hygroscopicity, and support metabolic disease treatment.

Engineered AAV capsids target CNS endothelium to deliver secretable hIDS across the blood-brain barrier and reduce brain GAG accumulation.

A pH 4-8 buffer system protects free-form protein drugs from digestive enzymes, enabling more stable oral delivery and bioactivity.

Targeting OGDH with KGD09 or KGD02 creates a metabolic vulnerability in p53-mutant cancers, reducing tumor growth and improving survival.

Targeting D5D with heterocyclic compounds lowers pro-inflammatory eicosanoids and supports treatment of metabolic and cardiovascular disorders.

Targeting reduced Na+/K+-ATPase activity with agonist antibodies or peptides helps protect beta cells, limit hyperglycemia, and reduce organ damage.

Novel spiro derivatives block the menin/MLL interaction with improved oral stability and half-life to reduce tumor growth in MLL-driven leukemia.

Selective inhibition of LBR/TM7SF2 and EBP lowers plasma cholesterol while sparing central nervous system cholesterol exposure.

An oral GLP-1 formulation uses bile salts and pH modifiers to avoid injections while maintaining glucose control and weight-loss benefits.

Cross-linking ALK1 with BMPRII or ActRII receptors restores SMAD signaling to address HHT-related vascular malformations.

Alternating alginic acid and polyornithine layers shield transplanted pancreatic islets from immune attack while extending blood glucose control.

Targeting metallothionein with humanized antibodies helps curb inflammation that shortens diabetes and liver disease treatment effects.

Formate with betaine or zinc lowers homocysteine while easing strict diet requirements in homocystinuria and extending treatment usefulness.

Polyacrylamide copolymer excipients keep insulin in a stable low-order state, limiting aggregation while enabling faster absorption.

Empagliflozin improves glycemic control through SGLT-2 inhibition while reducing oxidative stress and cardiovascular event risk in diabetes.

High-affinity anti-BDCA2 antibodies target plasmacytoid dendritic cells to inhibit cytokine secretion and support autoimmune therapy.

Combining CBDA-class AMPK activators with SGLT2 inhibitors boosts AMPK activation while improving metabolic health with lower adverse-effect risk.

Site-specific PGA mutations improve immobilized enzyme stability and activity, enabling efficient insulin deprotection and free insulin production.

Covalent GPCR conjugates with bile salts or lipophilic moieties improve oral absorption, protein binding, and circulating half-life.

Salt formation with diethanolamine improves ursolic acid efficacy for muscle hypertrophy, fat reduction, and glucose tolerance.

Targeted A13Aib and N24E substitutions improve GIP antagonist solubility and aqueous stability for ready-to-use liquid formulations.

Low-affinity anti-aP2 antibodies neutralize secreted aP2 without raising circulating levels, improving glucose metabolism and insulin sensitivity.

By linking insulin dimers to incretin peptides, this case shows glucose control with basal-like action and lower hypoglycemia risk.

Green tea extract aggregates microplastics in the body to limit absorption while reducing inflammation, oxidative stress, and lipid metabolism disorders.

A Taraxacum platycarpum and Lonicerae japonica extract blend reduces body fat and cholesterol while avoiding the side effects of conventional obesity treatments.

Fusion-stabilized GLP1R libraries enable reliable antibody discovery despite low GPCR expression and purification instability.

Migalastat stabilizes selected mutant α-Gal A enzymes, improving trafficking and reducing substrate buildup in mutation-specific Fabry treatment.

Tailored acyl groups at insulin’s B29 lysine extend action, improve bioavailability and stability, and reduce injection frequency.

Microbial single-cell protein replaces animal protein in vegan pet feed to cut allergenicity while improving digestibility and bowel health.

Small IL-4 α-helix C peptide fragments target innate kidney inflammation in diabetic nephropathy and lower urinary albumin and KIM-1.

Histidine helps protect GLP-1 agonists from SNAC-related degradation while retaining oral absorption and extending storage stability.

A defined Roseburia hominis and Eubacterium eligens composition uses microbial metabolites to improve glucose homeostasis in type 2 diabetes.